ABSTRACT
Some patients who undergo cardiac surgery have reduced cardiac function,
which can often make anesthesia management difficult owing to severe
hypotension at the time of anesthesia induction. Therefore, it is
important to select drugs that cause minimal circulatory depression. On
the other hand, in 2020, the use of remimazolam, a short-acting
benzodiazepine sedative, was approved in Japan, and reports of its use
in various patients have been increasing. This drug has the
characteristic of causing minimal effects on circulation. We here report
the safe use of remimazolam in the anesthesia management of a patient
with decreased cardiac function who was diagnosed as having angina
pectoris. The patient was a 73-year-old man scheduled for
coronary artery bypass graft
(CABG) surgery. Remimazolam was used for sedation purposes during
anesthesia induction. During surgery, there were no significant
hemodynamic changes and the patient remained in stable cardiovascular
condition. Our present case indicates that remimazolam can be considered
as an option for anesthesia management in CABG for patients with
decreased cardiac function.